John Buchanan
Dr. John Buchanan serves as the President and CEO for the Center for Aquaculture Technologies (CAT), a team with a corporate strategy of maintaining excellence in contract research and innovative R&D in aquaculture biotechnology. Prior to helping launch CAT, Dr. Buchanan spent 5 years as the Director of Research and Development at AquaBounty Technologies. Previously, Dr. Buchanan has held a series of research leadership positions at Louisiana State University, the University of California at San Diego School of Medicine, and Kent SeaTech Corporation. Dr. Buchanan has led research on the application of genetic engineering to aquaculture, the use of selective breeding, hatchery technologies, and genomics for improved productivity in finfish, the development of novel therapeutics for aquaculture, and the molecular and genetic basis for virulence in aquatic and human pathogens. He also has experience directing and conducting studies compliant with governmental regulatory standards (GLP/GCP).
Dr. Buchanan completed his undergraduate work at Texas A&M University with a B.S. in Zoology, and received his Ph.D. in Oceanography from Louisiana State University with a focus on marine biotechnology.
Specialties: business development, corporate strategy, genetic engineering, infectious disease, molecular microbiology, vaccine development, biotechnology, molecular biology, ploidy manipulation, cryopreservation, GLP, GCP, regulatory studies
Fernanda Hoe
- Veterinary Medicine degree from Unesp - Botucatu, Brazil
- Master in Science from the University of Wisconsin, USA
- MBA from FGV, Brazil.
- More than 15 years of experience in the Animal Health Industry. Experience in technical, sales, marketing with focus on customer insights, product positioning and launching. Since 2016 leading the R&D team in Brazil.
Dr Jordan Kerns
Jack Oswald
Reza Zadeh
Reza Bosagh Zadeh is Founder CEO at Matroid and an Adjunct Professor at Stanford University. His work focuses on Machine Learning, Distributed Computing, and Discrete Applied Mathematics. Reza received his PhD in Computational Mathematics from Stanford under the supervision of Gunnar Carlsson. His awards include a KDD Best Paper Award and the Gene Golub Outstanding Thesis Award. He has served on the Technical Advisory Boards of Microsoft and Databricks. As part of his research, Reza built the Machine Learning Algorithms behind Twitter's who-to-follow system, the first product to use Machine Learning at Twitter. Through Apache Spark, Reza's work has been incorporated into industrial and academic cluster computing environments. In addition to research, Reza designed and teaches two PhD-level classes at Stanford: Distributed Algorithms and Optimization (CME 323), and Discrete Mathematics and Algorithms (CME 305).
Dr Luis Gosalbez
Luis is the Director of Business Development at OptiBiotix Health in the UK. Previously, he held different positions in the biotechnology industry and in pharmaceutical consulting in Spain and Germany. His scientific career was developed between Universidad Complutense de Madrid, Centro de Biología Molecular Severo Ochoa-CSIC (both in Spain) and the Korea Advanced Institute of Science and Technology (KAIST, South Korea). His research was always focused on microbiology, the human microbiome and on the development of antimicrobials and antivirals. He received his BSc and MSc in Biotechnology from Universidad Complutense de Madrid, his PhD in Life Sciences from the Catholic University of San Antonio (Spain) and a Master’s in Bioscience Enterprise from the University of Cambridge in the UK.
Dr Soren Krogsgaard Thomsen
Dr Soren Krogsgaard Thomsen is co-founder and CEO of the UK-based start-up company BioMe Oxford. Trained in medical genetics at the Universities of Oxford and Cambridge, Soren has a background in both academic and industrial life sciences research. His publication record spans work on the genetics of complex diseases and academic entrepreneurship. Since co-founding BioMe Oxford, he has successfully led the company to raising pre-seed investment, winning a number of international business competitions along the way (incl. Imagine IF and Idea Idol). Soren dreams of enabling a revolution in precision medicine through population-wide studies of our second genome within.